These results have implications for therapeutic targeting of NRAS mutant melanomas where a dual BRAF/CRAF inhibitor or a BRAF and a PIK3CA inhibitor or a MEK and a PIK3CA inhibitor in combination is likely to show efficacy in the clinic. This evidence concerns the gene BRAF and melanoma.